EDA2R-NIKシグナリングは,がんカシェキアに関連した筋肉縮を促進する
Sevval Nur Bilgic1, Aylin Domaniku1, Batu Toledo1
1Department of Molecular Biology and Genetics, Koc University, Istanbul, Turkey.
Nature
|May 10, 2023
まとめ
癌に関連した筋肉衰弱 (カケキシア) は,エクトディスプラシンA2受容体 (EDA2R) のシグナル伝達が増加する. EDA2Rとその下流のNIK経路をターゲットにすることで,がん患者の筋肉喪失を防ぐことができます.
科学分野:
- 生物化学
- 分子生物学
- 腫瘍学
背景:
- 骨格筋の縮はがんカシェキアの重要な特徴で,生存率と生活の質を低下させる.
- 筋疲労に対する現在の治療法は, 基礎となるメカニズムの理解が不十分であるため, 制限されています.
- エクトディスプラシンA2受容体 (EDA2R) は,がんに関連した筋肉縮において上位調節される.
研究 の 目的:
- 骨格筋縮におけるEDA2R信号伝達の役割を調査する.
- EDA2Rの活性化によって筋肉の衰えが起こる 分子メカニズムを解明する.
- 癌に関連した筋肉の喪失を防ぐための潜在的な治療目標を探る.
主な方法:
- 腫瘍を持つマウスとヒトの癌患者の遺伝子発現分析
- 主要なミオチューブをEDA2RリガンドEDA-A2で刺激する.
- 筋肉縮に関連する遺伝子発現の評価 (Atrogin1, MuRF1)
- NF-kappaB (NFB) 経路の活性化とNFκB誘導キナーゼ (NIK) の活性に関する調査.
- EDA2RとNIKのノックアウトマウスとオンコスタチンM (OSM) /オンコスタチンM受容体 (OSMR) のノックアウトマウスを用いた体内試験.
主要な成果:
- 骨髄管のEDA2R活性化により,アトロフィー関連遺伝子のAtrogin1とMuRF1が発現した.
- EDA2R媒介の縮は,非正規のNFB経路とNIK活性に関与した.
- EDA- A2の過剰発現はマウスの筋肉衰弱を引き起こし,EDA2RまたはNIKの消去はそれに対して保護された.
- 腫瘍に由来するOSMはEDA2Rの発現を向上させた.
- OSMRのノックアウトマウスは腫瘍誘発の筋肉衰弱に抵抗性がありました.
結論:
- 腫瘍に由来するOSMによってOSMR経路を通じて活性化されるEDA2Rシグナリングは,癌に関連した骨格筋縮を誘発する.
- EDA2R-NIKシグナル伝達軸は,がんにおける筋肉の衰えを媒介する重要な要素である.
- EDA2R-NIKまたはOSM-OSMR経路をターゲットにすることは,がん患者の筋肉喪失を防ぐための潜在的な治療戦略を提供します.
関連する概念動画
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
PI3K/mTOR/AKT Signaling Pathway
3.7K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.7K
Cross-bridge Cycle
117.8K
As muscle contracts, the overlap between the thin and thick filaments increases, decreasing the length of the sarcomere—the contractile unit of the muscle—using energy in the form of ATP. At the molecular level, this is a cyclic, multistep process that involves binding and hydrolysis of ATP, and movement of actin by myosin.
117.8K
Mitogens and the Cell Cycle
6.6K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K
Satellite Stem Cells and Muscular Dystrophy
2.0K
Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...
2.0K
Electron Transport Chain: Complex I and II
14.6K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
14.6K


